Clinical trials: Antiplatelet Therapy
Coronary Artery Disease
PITT PCI Xience Registry
Stents are devices utilized to treat cholesterol blockages of the coronary (heart) arteries. The introduction of drug-eluting (coated) stents into clinical practice is regarded as a revolutionary breaktrhough, as it has reduced…
- Trial name
- NCT01299207
- Where
- United States
- Volunteers
- 2,506 people
- Sponsor
- University of Pittsburgh
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement
Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI
TAVI is increasingly adopted as standard treatment for many subgroups of patients with aortic stenosis. However, due to a lack of data there is yet no TAVI-specific guidance regarding the optimum periinterventional drug regimen.
- Conditions
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Intracranial Embolism
- Trial name
- DAPT-TAVI (NCT03001960)
- Testing
- Preloading before TAVI, Postloading after TAVI
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Acute Cardiac Syndrome, Stent Thrombosis
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)
The main objective of the project is to assess the long-term prognostic impact of residual platelet reactivity after optimal antiplatelet therapy in a large cohort of patients with acute coronary syndrome undergoing invasive…
- Conditions
- Acute Cardiac Syndrome, Stent Thrombosis, Platelet Function, Antiplatelet Therapy
- Trial name
- RECLOSE2-ACS (NCT01231035)
- Where
- Italy
- Volunteers
- 1,789 people
- Sponsor
- Careggi Hospital
STEMI - ST Elevation Myocardial Infarction
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition.
- Trial name
- NCT06013020
- Testing
- NOAC+DAPT, DAPT
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Zunyi Medical College
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.
- Trial name
- DAPTShort (NCT06075420)
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Genoss Co., Ltd.
Coronary Artery Disease
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting.
- Trial name
- SWAP-5 (NCT04634162)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Florida
Coronary Artery Disease, Acute Coronary Syndrome
Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment
The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to an adjusted thienopyridine treatment on STEMI…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Genetic Resistance to Clopidogrel, Compliance to Thienopyridine Treatment
- Trial name
- GIANT (NCT01134380)
- Where
- 12 sites in France
- Volunteers
- 1,500 people
- Sponsor
- Biotronik France
Tracheostomy Hemorrhage
Tracheotomy With and Without Dual Antiplatelet Therapy
Platelet-inhibiting drugs are often used after vascular interventions. Patients who require such therapies are often critically ill, are treated in intensive care units and often require long-term ventilation.
- Trial name
- PDT and (D)APT (NCT05058469)
- Testing
- Tracheotomy
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Asklepios Neurological Clinic Bad Salzhausen
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy
Patients who developed an acute coronary syndrome despite dual antiplatelet therapy with aspirin and clopidogrel may benefit from a further dose of clopidogrel before a percutaneous coronary intervention.
- Trial name
- NCT01572129
- Testing
- Clopidogrel
- Where
- 2 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Campus Bio-Medico University
Acute Coronary Syndrome
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary…
- Trial name
- TACSI (NCT03560310)
- Testing
- Ticagrelor 90mg twice daily and ASA 75-100 mg daily, ASA 75-160 mg daily
- Where
- 22 sites in Denmark, Finland and 3 more
- Volunteers
- 2,201 people
- Sponsor
- Vastra Gotaland Region
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influence of PRU Values on Primary Outcome
High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures
Antiplatelet therapy with clopidogrel is recommended following peripheral endovascular procedures. The clinical significance of an inadequate response to clopidogrel following percutaneous coronary interventions has been recently…
- Trial name
- PRECLOP (NCT01744613)
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Patras
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Ischemic Stroke
Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
- Trial name
- Bo-CRISP (NCT01843361)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Ruhr University of Bochum
Coronary Heart Disease
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB)…
- Trial name
- NCT06088433
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Coronary Artery Disease, Percutaneous Coronary Intervention
The xDAPT External Validation Study
Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications.
- Trial name
- xDAPT (NCT06736626)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Aneurysm Cerebral, Endovascular Procedures
Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling
Comparison of duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms
- Trial name
- NCT05257824
- Testing
- Aspirin 100mg, Clopidogrel 75mg
- Where
- 8 sites in South Korea
- Volunteers
- 528 people
- Sponsor
- Seoul National University Bundang Hospital